Apellis Pharmaceuticals, Inc. Common Stock
APLS
$41.03
-0.07%
Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapies that inhibit the complement system at the C3 protein level to treat diseases with high unmet need. The company has established itself as a pioneer in complement inhibition with two marketed drugs, SYFOVRE and EMPAVELI, targeting geographic atrophy and paroxysmal nocturnal hemoglobinuria, respectively. The current investor narrative is dominated by a major strategic acquisition, as evidenced by recent headlines detailing Biogen's blockbuster deal to acquire Apellis, which has fundamentally reshaped the company's future and driven significant stock price volatility as the market assesses the long-term growth prospects versus near-term integration risks.…
APLS
Apellis Pharmaceuticals, Inc. Common Stock
$41.03
Related headlines
Investment Opinion: Should I buy APLS Today?
Rating & Thesis: Hold. The investment thesis is that the fundamental value of Apellis has been largely realized through the Biogen acquisition, leaving the stock technically overextended and facing integration execution risk, which limits near-term upside despite solid long-term assets.
Supporting Evidence: The stock trades at a trailing PS ratio of 3.15 and an EV/Sales of 5.22, which is reasonable for a commercial-stage biotech but offers limited margin of safety at the peak. While analyst revenue estimates average a promising $1.53B, the wide 27.6% spread indicates high uncertainty. Profitability remains inconsistent (Q4 net margin: -29.49%), and the stock's 81.40% 3-month surge has pushed it to extreme technical levels, trading within pennies of its 52-week high.
Risks & Conditions: The two biggest risks are a technical reversal from the $41 resistance level and disappointing post-acquisition revenue growth. This Hold rating would upgrade to Buy only if the stock experiences a healthy pullback (e.g., toward the $30-$35 range) on non-fundamental news, improving the risk/reward profile. It would downgrade to Sell if Q1 2026 earnings post-acquisition show significant revenue deceleration or if the price breaks decisively below key support at $35. The stock is currently fairly valued relative to its new status as an acquisition target but overvalued from a short-term momentum perspective.
Sign up to view all
APLS 12-Month Price Forecast
The outlook is neutral with a base-case bias, as the explosive upside from the Biogen deal appears priced in, leaving limited near-term catalysts for further appreciation. The wide analyst estimate dispersion and inconsistent earnings profile justify caution. The stock is likely to trade sideways to slightly down as it digests its massive gains, with direction heavily dependent on the first few quarterly reports under Biogen's stewardship. The stance would upgrade to bullish on a pullback to the mid-$30s that improves the risk/reward, or on clear evidence of revenue acceleration. It would turn bearish on a breakdown below $35 or significant integration missteps.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Apellis Pharmaceuticals, Inc. Common Stock's 12-month outlook, with a consensus price target around $53.34 and implied upside of +30.0% versus the current price.
Average Target
$53.34
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$33 - $53
Analyst target range
Analyst coverage for Apellis is substantial, with 9 firms providing estimates, indicating strong institutional interest. The consensus sentiment appears cautiously optimistic, though the provided data lacks explicit Buy/Hold/Sell distribution and an average target price, so the implied upside cannot be calculated. The analyst revenue estimates for the forward period show a wide range, with a low of $1.36 billion, an average of $1.53 billion, and a high of $1.74 billion, representing a spread of approximately 27.6% from low to high. This wide dispersion signals significant uncertainty among analysts regarding the company's future revenue trajectory, likely tied to integration risks post-acquisition and the commercial uptake of its key drugs. Recent institutional rating actions from late 2024 show a mix of Buy, Outperform, Neutral, and Equal Weight ratings, with no major downgrades evident at that time, suggesting a generally stable but not uniformly bullish analyst view prior to the acquisition announcement.
Bulls vs Bears: APLS Investment Factors
The bull case, currently stronger, is anchored by the transformative Biogen acquisition which crystallized value and propelled the stock to new highs. The bear case centers on the stock's extreme technical overextension following a 104% annual gain and the company's persistent inability to deliver consistent profitability. The single most important tension in the investment debate is whether Biogen's commercial muscle and strategic focus can accelerate revenue growth enough to justify the stock's post-acquisition valuation and overcome the inherent volatility in Apellis's financials, or if integration challenges and profit-taking will lead to a significant pullback from current peak levels.
Bullish
- Blockbuster Acquisition by Biogen: Biogen's acquisition of Apellis validates the long-term value of its two marketed complement inhibitors, SYFOVRE and EMPAVELI, and provides a strategic exit for shareholders at a significant premium. The deal triggered a 136% single-day price jump from ~$17 to over $40, reflecting the market's assessment of the transaction's value.
- Strong Gross Margins and Cash Position: The company boasts a robust trailing-twelve-month gross margin of 89.81%, indicating highly profitable core drug sales. It ended Q4 2025 with $467.8 million in cash and generated positive free cash flow of $45.33 million over the TTM, providing financial stability through the acquisition process.
- Analyst Revenue Growth Expectations: Analysts project significant revenue growth, with an average forward estimate of $1.53 billion, representing a substantial increase from recent quarterly run rates. The high estimate of $1.74 billion suggests a potential upside scenario if commercial execution post-acquisition exceeds expectations.
- Valuation Re-rating Post-Commercialization: The current Price-to-Sales (PS) ratio of 3.15 is near the lower end of its historical range post-commercialization, having compressed from extremes above 100x. This suggests the market may be pricing in a more stable growth profile, potentially leaving room for multiple expansion if Biogen successfully accelerates sales.
Bearish
- Extreme Technical Overextension: The stock trades at 99.9% of its 52-week high ($40.96 vs. $41.0) after a 103.98% one-year surge, indicating severe vulnerability to profit-taking. The negative 1-month relative strength of -8.57% versus the market's 9.98% gain suggests the explosive move is consolidating and momentum may be waning.
- Highly Inconsistent Profitability: The company swings wildly between profit and loss, as evidenced by Q3 2025 net income of $215.7 million followed by a Q4 2025 net loss of -$58.95 million. The thin operating margin of 5.52% (TTM) highlights the challenge of translating high gross margins into sustainable bottom-line results.
- Leveraged Balance Sheet: Apellis carries a debt-to-equity ratio of 1.31, indicating a leveraged capital structure that could pressure financial flexibility. While the current ratio of 3.14 is strong, the elevated debt level adds risk, especially during the integration phase with a new parent company.
- Analyst Uncertainty on Revenue Trajectory: Analyst revenue estimates for the forward period show a wide 27.6% spread from low ($1.36B) to high ($1.74B), signaling significant uncertainty about post-acquisition commercial execution. This dispersion reflects integration risks and questions about the growth trajectory of SYFOVRE and EMPAVELI under Biogen.
APLS Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 103.98% gain over the past year. As of the latest close at $40.96, the price is trading at approximately 99.9% of its 52-week high of $41.0, indicating the stock is at its absolute peak and may be vulnerable to profit-taking or overextension. This positioning near the highs reflects extreme bullish momentum but also suggests limited immediate upside before encountering significant technical resistance. Recent momentum has been exceptionally strong, with the stock surging 81.40% over the last three months and 1.41% over the past month, though the 1-month gain notably lags the broader market's 9.98% rise, as indicated by a negative relative strength of -8.57. This divergence suggests the stock's explosive move may be consolidating or that the market is digesting the massive gains from the late-March price jump from ~$17 to over $40. Key technical levels are clearly defined, with immediate resistance at the 52-week high of $41.0 and support at the 52-week low of $16.1. A decisive breakout above $41.0 could signal a continuation of the bullish trend, while a failure could lead to a pullback. The stock exhibits a negative beta of -0.197, indicating it has moved inversely to the market over the measured period, which is atypical and likely driven by idiosyncratic, company-specific events like the acquisition news rather than systematic market moves, implying high event-driven volatility.
Beta
-0.25
-0.25x market volatility
Max Drawdown
-43.5%
Largest decline past year
52-Week Range
$16-$41
Price range past year
Annual Return
+137.4%
Cumulative gain past year
| Period | APLS Return | S&P 500 |
|---|---|---|
| 1m | +0.5% | +8.2% |
| 3m | +86.1% | +9.0% |
| 6m | +101.8% | +10.5% |
| 1y | +137.4% | +26.5% |
| ytd | +58.7% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
APLS Fundamental Analysis
Revenue growth has been volatile on a quarterly basis, with the most recent Q4 2025 revenue of $199.9 million representing a 5.94% year-over-year decline. However, this follows an exceptionally strong Q3 2025 where revenue was $458.6 million, indicating significant quarter-to-quarter lumpiness likely tied to drug launch dynamics and timing of partner payments. The revenue segment data shows product sales of $190.3 million and licensing/other revenue of $9.6 million for the latest period, confirming the commercial focus. The company's path to profitability remains inconsistent; while it posted a substantial net income of $215.7 million in Q3 2025, it returned to a net loss of -$58.95 million in Q4 2025. Gross margin remains robust at 89.81% (TTM), but operating margin is thin at 5.52%, highlighting the high cost structure of a commercial-stage biotech. The quarterly net margin was -29.49% in Q4, demonstrating the challenge of translating high gross margins into consistent bottom-line profitability. The balance sheet and cash flow position appears solid, with a strong current ratio of 3.14 and free cash flow over the trailing twelve months of $45.33 million. However, the debt-to-equity ratio of 1.31 indicates a leveraged capital structure. Return on equity is a modest 6.05%, and the company holds substantial cash, ending Q4 with $467.8 million, which provides a runway for operations but must be weighed against the acquisition's impact on the financials.
Quarterly Revenue
$199913000.0B
2025-12
Revenue YoY Growth
-0.05%
YoY Comparison
Gross Margin
+0.85%
Latest Quarter
Free Cash Flow
$45327000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is APLS Overvalued?
Given the inconsistent profitability, with recent quarterly net income negative, the Price-to-Sales (PS) ratio is the most appropriate primary valuation metric. Apellis trades at a trailing PS ratio of 3.15 and an Enterprise Value-to-Sales (EV/Sales) of 5.22. The forward-looking sales multiple implied by analyst estimates for revenue of ~$1.53 billion suggests a significant discount if those estimates are achieved, pointing to market expectations of substantial top-line growth. Compared to typical biotechnology industry averages, a PS ratio in the low-to-mid single digits can be considered reasonable for a company with marketed products but ongoing losses; however, a direct industry average from the provided data is not available for a precise spread calculation. Historically, the stock's own valuation has undergone a dramatic compression and subsequent re-rating. The PS ratio has fluctuated wildly from extremes above 100x in 2021-2022 down to the current 3.15x, reflecting the transition from a pre-revenue, high-burn biotech to a commercial entity. The current PS is near the lower end of its own historical spectrum post-commercialization, which could suggest the market is pricing in a more stable, mature growth profile or skepticism about future expansion following the acquisition.
PE
141.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -30x~3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
45.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Apellis exhibits high financial volatility, with quarterly net income swinging from a $215.7 million profit in Q3 2025 to a -$58.95 million loss in Q4 2025. This inconsistency, coupled with a leveraged balance sheet (debt-to-equity of 1.31), creates earnings risk. While gross margins are robust at 89.81%, the thin operating margin of 5.52% reveals a high cost structure, making the path to consistent profitability uncertain. Revenue also shows lumpiness, declining 5.94% YoY in Q4 2025 after a strong Q3, indicating potential dependence on timing of partner payments or drug launch dynamics.
Market & Competitive Risks: The primary market risk is severe valuation compression from current peak levels. Trading at 99.9% of its 52-week high after a 104% annual gain, the stock is highly susceptible to profit-taking. The negative beta of -0.197 indicates its moves are driven by idiosyncratic events (the acquisition) rather than market fundamentals, implying high event-driven volatility that may subside. Competitive risks remain in the dynamic biotechnology landscape for complement inhibitors, and the success of the acquisition now hinges on Biogen's integration execution and ability to outpace competitors.
Worst-Case Scenario: The worst-case scenario involves a breakdown in the Biogen acquisition rationale, leading to failed commercial synergies, a sharp deceleration in revenue growth toward the analyst low estimate of $1.36B, and a return to sustained quarterly losses. This could trigger a mass exodus of momentum investors, reverting the stock toward its pre-acquisition trading range. A realistic downside could see the stock fall to its 52-week low of $16.1, representing a potential loss of approximately -61% from the current price of $40.96, especially if the technical support from the late-March gap fails to hold.
FAQ
The key risks are: 1) Technical Reversal Risk: The stock is at its 52-week high after a massive rally, making it highly vulnerable to profit-taking (max drawdown potential: -61% to the 52-week low). 2) Execution/Integration Risk: The success of the Biogen deal is not guaranteed; poor integration could slow revenue growth toward the analyst low estimate of $1.36B. 3) Financial Volatility Risk: The company's earnings are highly inconsistent, swinging from a $215.7M profit to a -$58.95M loss in consecutive quarters. 4) Leverage Risk: A debt-to-equity ratio of 1.31 adds financial risk during a period of transition.
The 12-month forecast is for consolidation with a neutral bias. The base case (55% probability) sees the stock trading between $38 and $42 as the market digests the acquisition gains and awaits proof of commercial execution. The bull case (25% probability) targets $45-$50 if Biogen accelerates growth, while the bear case (20% probability) warns of a pullback to $20-$30 if integration falters. The most likely scenario is range-bound trading, with the key assumption being that revenue grows in line with the analyst average estimate without major surprises.
APLS appears fairly valued relative to its new status as an acquired entity but overextended from a technical perspective. With a trailing Price-to-Sales ratio of 3.15 and an EV/Sales of 5.22, it trades within a reasonable range for a commercial-stage biotech with marketed products. However, this valuation follows a dramatic compression from historical extremes and offers little discount. The market is pricing in successful execution of the Biogen acquisition and revenue growth toward the analyst average of $1.53B. Any stumble could make the current valuation look expensive.
APLS is not a compelling buy at the current price of $40.96. While the Biogen acquisition validates its long-term assets, the stock has already surged 104% over the past year and trades at its 52-week high, pricing in much of the near-term optimism. The risk/reward is unfavorable for new buyers, as the potential upside is limited by technical resistance at $41, while a pullback to support levels near $30 represents a -25% downside. It could become a good buy for patient investors only on a significant pullback that improves the margin of safety.
APLS is unsuitable for short-term trading due to its event-driven volatility (negative beta of -0.197) and position at a technical peak. For long-term investors, the horizon is now tied to Biogen's multi-year integration and growth plan. A minimum holding period of 12-18 months is suggested to assess post-acquisition performance through several earnings cycles. The stock does not pay a dividend and remains a growth-oriented, speculative holding, making it appropriate only for the growth portion of a diversified portfolio with a long-term view.